FDA
FDA Articles
Stealth Bio stock more than doubled on Tuesday after the company announced a critical update from the FDA.
Published:
Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of late.
Published:
Karyopharm Therapeutics shares made a handy gain on Wednesday after the firm secured a key FDA nod for its relapsed or refractory diffuse large B-cell lymphoma treatment.
Published:
Agile Therapeutics shares took a dip on Tuesday after the company announced a key FDA approval for its new weekly contraceptive patch. Yet, one analyst sees great long-term potential, targeting the...
Published:
Aimmune Therapeutics shares jumped early on Monday after the FDA announced late Friday a critical approval for the firm’s peanut allergy treatment.
Published:
Neurotrope released a corporate update after analyzing data from its recently reported Phase 2 confirmatory clinical trial examining moderately severe to severe Alzheimer's disease patients.
Published:
When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. For Genprex, it was a nod from...
Published:
This past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these standouts to highlight.
Published:
Durect shares dropped early on Friday after an FDA committee vote on Posimir, the company’s pain relief treatment.
Published:
Nektar Therapeutics shares were crushed on Wednesday after the FDA did not recommend the company’s pain drug.
Published:
An FDA nod for NanoFlu, a recombinant quadrivalent seasonal influenza vaccine candidate, offered a boost to Novavax shares on Wednesday.
Published:
Aquestive Therapeutics' shares lost nearly a third on Monday after the firm received an update from the FDA concerning its seizure treatment.
Published:
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Published:
Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed...
Published:
Neovasc shares nearly doubled on Tuesday after the firm announced the submission of an application to the FDA for its Neovasc Reducer medical device for the treatment of refractory angina.
Published: